{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', '7.8.', 'Treatment after the End of the Study', '66', '8.', 'DISCONTINUATION CRITERIA', '66', '8.1.', 'Discontinuation of Study Treatment', '66', '8.2.', 'Safety Stopping Criteria', '67', '8.2.1.', 'Liver Chemistry Stopping Criteria', '67', '8.2.2.', 'Study Treatment Restart or Rechallenge', '68', '8.2.3.', 'QTc Interval Stopping Criteria', '68', '8.2.4.', 'Left Ventricular Ejection Fraction (LVEF) Stopping Criteria', '69', '8.2.5.', 'Corneal Event Stopping Criteria', '69', '8.2.6.', 'Infusion-Related Reaction Management and Stopping', 'Criteria', '70', '8.2.7.', 'Allergic and Anaphylactic Reaction Stopping Criteria', '70', '8.3.', 'Withdrawal from the Study', '70', '8.4.', 'Lost to Follow Up', '70', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', '71', '9.1.', 'Efficacy Assessments', '74', '9.1.1.', 'Independent Review Committee', '76', '9.2.', 'Adverse Events', '76', '9.2.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', '76', '9.2.2.', 'Method of Detecting AEs and SAEs', '77', '9.2.3.', 'Follow-up of AEs and SAEs', '77', '9.2.4.', 'Regulatory Reporting Requirements for SAEs', '77', '9.2.5.', 'Cardiovascular and Death Events', '77', '9.2.6.', 'Disease-Related Events and/or Disease-Related', '78', '9.2.7.', 'Adverse Events of Special Interest', '78', '9.2.8.', 'Pregnancy', '78', '9.2.9.', 'Ocular Examinations and Procedures', '79', '9.2.10.', 'Ocular Sub-Study Examinations', '79', '9.2.10.1.', 'Monocular prophylaxis', '80', '9.2.10.2. Monocular treatment', '81', '9.2.10.3.', 'Sub-Study Exams', '81', '9.3.', 'Treatment of Overdose', '82', '9.4.', 'Safety Assessments', '82', '9.4.1.', 'Physical Examinations', '82', '9.4.2.', 'ECOG Performance Status', '82', '9.4.3.', 'Vital Signs', '82', '9.4.3.1.', 'First Infusion', '83', '9.4.3.2.', 'Subsequent Infusions', '83', '9.4.4.', 'Electrocardiogram', '83', '9.4.5.', 'Echocardiogram', '83', '9.4.6.', 'Laboratory Assessments', '83', '9.4.7.', 'Patient-Reported Outcome Version of the Common Term', 'Criteria for Adverse Events (PRO-CTCAE)', '84', '9.4.8.', 'Visual Function Questionnaires', '84', '9.4.8.1.', 'National Eye Institute Visual Function', 'Questionnaire-25', '85', '9.4.8.2.', 'The Ocular Surface Disease Index', '85', '9.5.', 'Pharmacokinetics', '85', '9.5.1.', 'Blood Sample Collection for Pharmacokinetics', '85', '7']['2017N330177_04', 'CONFIDENTIAL', '205678', '9.5.2.', 'Pharmacokinetic Sample Analysis', '85', '9.6.', 'Immunogenicity', '86', '9.7.', 'Translational Research', '86', '9.8.', 'Genetics', '86', '9.9.', 'Tumor Biomarker Analysis', '86', '9.9.1.', 'sBCMA Sample Analysis', '86', '9.9.2.', 'Potential Tumor Related Biomarkers', '87', '9.10.', 'Evaluation of Anti-Cancer Activity', '87', '9.11.', 'Health-Related Quality-of-Life', '88', '9.11.1.', 'European Organization for Research and Treatment of', 'Cancer Quality of Life Questionnaire 30-item Core module', '(EORTC QLQ-C30)', '88', '9.11.2.', 'European Organization for Research and Treatment of', 'Cancer Quality of Life Questionnaire 20-item Multiple', 'Myeloma module (EORTC QLQ-MY20)', '88', '9.11.3. Qualitative Telephone Interviews (Patient Interviews)', '89', '10. STATISTICAL CONSIDERATIONS', '89', '10.1. Hypothesis Testing', '89', '10.2.', 'Sample Size Determination', '90', '10.3.', 'Sample Size Sensitivity', '90', '10.4.', 'Populations for Analysis', '91', '10.5.', 'Statistical Analyses', '91', '10.5.1.', 'Efficacy Analyses', '92', '10.5.2.', 'Safety Analyses', '94', '10.5.3.', 'Analyses of Health-Related Quality of Life Data', '95', '10.5.4.', 'Pharmacokinetic Analyses', '95', '10.5.4.1. Pharmacokinetic Data Analyses', '95', '10.5.4.2. Statistical Analysis of Pharmacokinetic Data', '96', '10.5.5.', 'Pharmacokinetic/Pharmacodynamic Analyses', '96', '10.5.6.', 'Translational Research Analyses', '96', '10.5.6.1. Analysis of Novel Biomarker Data', '96', '10.5.6.2.', 'Analysis of Genetic Data', '96', '10.5.6.3.', 'Exploratory Analyses of DNA and Protein Data', '96', '10.5.7.', 'Analyses of Immunogenicity Data', '97', '10.5.8.', 'Other Analyses', '97', '10.5.9.', 'Interim Analyses', '97', '10.5.9.1. Futility Stopping Rule Based on Group', 'Sequential Design', '97', '10.5.9.2.', 'Additional Comparative Futility Stopping Rule', 'Based on Bayesian Approach', '98', '11. REFERENCES', '100', '12. APPENDICES', '105', '12.1.', 'Appendix 1: Abbreviations and Trademarks', '105', '12.2.', 'Appendix 2: Clinical Laboratory Tests', '110', '12.3.', 'Appendix 3: Study Governance Considerations', '111', '12.4.', 'Appendix 4: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '116', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', '122', '8']\n\n###\n\n", "completion": "END"}